CD38 is highly expressed on the surface of malignant plasma cells, functions as a receptor for CD31, has ectoenzymatic activities and is already targeted with monoclonal antibodies (daratumumab and isatuximab) in patients with MM (67, 68). Here, CD38 is linked to Miyoshi myopathy.